Leggett Andrew R, Berg Ari R, Hullinger Heidi, Benevenia Joseph B
Department of Orthopaedics, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
New Jersey Spine Specialists, Summit, NJ 07901, USA.
Diagnostics (Basel). 2022 Mar 30;12(4):857. doi: 10.3390/diagnostics12040857.
(1) Background: Giant Cell Tumor of the spine remains a difficult tumor to treat. Recent advances in adjuvant therapy such as denosumab and innovations in surgical technique in the last 5 years have given providers new options for treatment after a successful diagnosis of the tumor. (2) Methods: Articles published between 1927 and 2021 were selected from PubMed and Scopus searches using key words "Giant Cell Tumor" AND "Lumbar Spine" AND "Treatment". Relevant articles were reviewed and selected by the authors. (3) Results: A total of 191 articles were discovered. Complete en bloc spondylectomy remains the most definitive treatment option; however, this surgery is challenging and carries a high rate of complication. New adjuvant therapies including denosumab offer a viable alternative to surgery. (4) En bloc spondylectomy remains the gold standard treatment for Giant Cell Tumor of the spine with the lowest published recurrence rate. The use of (neo)adjuvant denosumab improves recurrence rates. More data are needed to determine if denosumab alone is a viable standalone definitive treatment.
(1) 背景：脊柱巨细胞瘤仍然是一种难以治疗的肿瘤。在过去5年中，诸如地诺单抗等辅助治疗的最新进展以及手术技术的创新为肿瘤确诊后提供了新的治疗选择。(2) 方法：从PubMed和Scopus数据库中检索1927年至2021年间发表的文章，检索关键词为“巨细胞瘤”、“腰椎”和“治疗”。作者对相关文章进行了回顾和筛选。(3) 结果：共发现191篇文章。整块全脊椎切除术仍然是最具决定性的治疗选择；然而，这种手术具有挑战性，且并发症发生率很高。包括地诺单抗在内的新辅助治疗为手术提供了可行的替代方案。(4) 整块全脊椎切除术仍然是脊柱巨细胞瘤的金标准治疗方法，其公布的复发率最低。使用（新）辅助地诺单抗可提高复发率。需要更多数据来确定单独使用地诺单抗是否是一种可行的独立确定性治疗方法。
Zotero 插件
